FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2088869449> ?p ?o ?g. }

• W2088869449 endingPage "1149" @default.
• W2088869449 startingPage "1138" @default.
• W2088869449 abstract "Pneumococcal conjugate vaccine, 7 valent (PCV7) is the most costly vaccine yet considered for publicly funded programs. In mid 2001, Australia funded PCV7 for high-risk groups only (indigenous children and children with certain underlying medical conditions). World wide, non-industry-funded studies and studies using cost-utility measures are sparse. We undertook an independent economic analysis of PCV7 compared with no vaccination in the non high-risk Australian childhood population using cost-utility and cost-effectiveness measures.The incidence of invasive pneumococcal disease (IPD), non-bacteraemic pneumonia and otitis media was estimated using representative urban Australian data, or by extrapolation from comparable industrialised countries. A decision-analytic model was developed for a hypothetical birth cohort using the age-specific vaccine coverage from the Californian randomised controlled trial of PCV7. Health outcomes were measured by life-years saved and deaths and disability-adjusted life-years (DALYs) averted. In line with government guidelines, only direct costs were considered in 1997-1998 Australian dollars.For a birth cohort of 250,000, the gross cost of vaccination is $ 78.6 million. Subtracting treatment cost savings, the net cost (discounted) is $ 61.7 million. In undiscounted terms, vaccination prevents 13.7 deaths, 11.2 (82%) from IPD and the remainder from non-bacteraemic pneumonia. The discounted cost per death avoided is $ 5.0 million, per life-year saved $ 230,130 and per DALY averted $ 121,100, giving a break-even vaccine price of $ 15.40 per dose. These estimates are most sensitive to the unit cost per dose of vaccine, estimates of incidence and vaccine efficacy against non-bacteraemic pneumonia and the discount rate. The cost per DALY reduced to $ 81,000 with a discount rate of 3% rather than 5% and to $ 90,000 with the most favourable assumptions concerning pneumonia reduction.With a vaccine price of $ 90 per dose, mid-range estimates of impact against non-bacteraemic pneumonia, and discount rate of 5%, a PCV7 program for infants not at high risk of IPD is at the upper limit of cost per DALY previously approved under Australian pharmaceutical funding guidelines. The impact of PCV7 against non-bacteraemic pneumonia is poorly defined, but its importance to cost-effectiveness in resource rich and resource poor settings warrants further studies or analysis to give greater precision to this outcome." @default.
• W2088869449 created "2016-06-24" @default.
• W2088869449 creator A5005901241 @default.
• W2088869449 creator A5031138177 @default.
• W2088869449 creator A5032844648 @default.
• W2088869449 creator A5042660118 @default.
• W2088869449 creator A5066224347 @default.
• W2088869449 creator A5075730026 @default.
• W2088869449 date "2004-03-01" @default.
• W2088869449 modified "2023-10-17" @default.
• W2088869449 title "The cost-effectiveness of pneumococcal conjugate vaccination in Australia" @default.
• W2088869449 cites W1977617775 @default.
• W2088869449 cites W1980228548 @default.
• W2088869449 cites W2004968413 @default.
• W2088869449 cites W2005883387 @default.
• W2088869449 cites W2010712225 @default.
• W2088869449 cites W2014360037 @default.
• W2088869449 cites W2014959064 @default.
• W2088869449 cites W2015843735 @default.
• W2088869449 cites W2023690749 @default.
• W2088869449 cites W2039437872 @default.
• W2088869449 cites W2044799438 @default.
• W2088869449 cites W2047469931 @default.
• W2088869449 cites W2049386698 @default.
• W2088869449 cites W2059608310 @default.
• W2088869449 cites W2071348182 @default.
• W2088869449 cites W2082215135 @default.
• W2088869449 cites W2100212030 @default.
• W2088869449 cites W2103637444 @default.
• W2088869449 cites W2104562710 @default.
• W2088869449 cites W2142965789 @default.
• W2088869449 cites W2148212653 @default.
• W2088869449 cites W215279680 @default.
• W2088869449 cites W2159189010 @default.
• W2088869449 cites W2162475738 @default.
• W2088869449 cites W2165631757 @default.
• W2088869449 cites W2167810611 @default.
• W2088869449 cites W2167888974 @default.
• W2088869449 cites W2334009089 @default.
• W2088869449 cites W274800124 @default.
• W2088869449 cites W2977187820 @default.
• W2088869449 doi "https://doi.org/10.1016/j.vaccine.2003.09.036" @default.
• W2088869449 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15003641" @default.
• W2088869449 hasPublicationYear "2004" @default.
• W2088869449 type Work @default.
• W2088869449 sameAs 2088869449 @default.
• W2088869449 citedByCount "52" @default.
• W2088869449 countsByYear W20888694492012 @default.
• W2088869449 countsByYear W20888694492013 @default.
• W2088869449 countsByYear W20888694492014 @default.
• W2088869449 countsByYear W20888694492015 @default.
• W2088869449 countsByYear W20888694492016 @default.
• W2088869449 countsByYear W20888694492018 @default.
• W2088869449 countsByYear W20888694492019 @default.
• W2088869449 countsByYear W20888694492021 @default.
• W2088869449 countsByYear W20888694492023 @default.
• W2088869449 crossrefType "journal-article" @default.
• W2088869449 hasAuthorship W2088869449A5005901241 @default.
• W2088869449 hasAuthorship W2088869449A5031138177 @default.
• W2088869449 hasAuthorship W2088869449A5032844648 @default.
• W2088869449 hasAuthorship W2088869449A5042660118 @default.
• W2088869449 hasAuthorship W2088869449A5066224347 @default.
• W2088869449 hasAuthorship W2088869449A5075730026 @default.
• W2088869449 hasConcept C112930515 @default.
• W2088869449 hasConcept C126322002 @default.
• W2088869449 hasConcept C127454912 @default.
• W2088869449 hasConcept C142724271 @default.
• W2088869449 hasConcept C144024400 @default.
• W2088869449 hasConcept C149923435 @default.
• W2088869449 hasConcept C187212893 @default.
• W2088869449 hasConcept C18903297 @default.
• W2088869449 hasConcept C203014093 @default.
• W2088869449 hasConcept C22070199 @default.
• W2088869449 hasConcept C2776125615 @default.
• W2088869449 hasConcept C2778049256 @default.
• W2088869449 hasConcept C2778866548 @default.
• W2088869449 hasConcept C2780664029 @default.
• W2088869449 hasConcept C2781253189 @default.
• W2088869449 hasConcept C2908647359 @default.
• W2088869449 hasConcept C3019080777 @default.
• W2088869449 hasConcept C523546767 @default.
• W2088869449 hasConcept C54355233 @default.
• W2088869449 hasConcept C64332521 @default.
• W2088869449 hasConcept C71924100 @default.
• W2088869449 hasConcept C72563966 @default.
• W2088869449 hasConcept C86803240 @default.
• W2088869449 hasConcept C99454951 @default.
• W2088869449 hasConceptScore W2088869449C112930515 @default.
• W2088869449 hasConceptScore W2088869449C126322002 @default.
• W2088869449 hasConceptScore W2088869449C127454912 @default.
• W2088869449 hasConceptScore W2088869449C142724271 @default.
• W2088869449 hasConceptScore W2088869449C144024400 @default.
• W2088869449 hasConceptScore W2088869449C149923435 @default.
• W2088869449 hasConceptScore W2088869449C187212893 @default.
• W2088869449 hasConceptScore W2088869449C18903297 @default.
• W2088869449 hasConceptScore W2088869449C203014093 @default.
• W2088869449 hasConceptScore W2088869449C22070199 @default.
• W2088869449 hasConceptScore W2088869449C2776125615 @default.

• next